Nitric oxide: A new biomarker of doxorubicin toxicity in children?

Pediatric Hematology and Oncology

Volumn 28, Issue 5, 2011, Pages 395-402

  Guler, Elif ^a   Baspinar, Osman ^a   Cekmen, Mustafa ^b   Kilinc, Metin ^a   Balat, Ayse ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

Author keywords

Cardiotoxicity; Children; Doxorubicin; Plasma total nitrite level

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; NITRATE; NITRIC OXIDE; NITRITE; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FRACTIONAL SHORTENING; HEART FUNCTION; HODGKIN DISEASE; HUMAN; M MODE ECHOCARDIOGRAPHY; MALE; NEPHROBLASTOMA; NITRITE BLOOD LEVEL; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; FEMALE; HEART; HUMANS; MALE; MEDIASTINUM; NEOPLASMS; NITRIC OXIDE; NITRITES; STROKE VOLUME;

EID: 79960126570     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.563373     Document Type: Article

References (34)

1. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827-834. (Pubitemid 9248185)
2. Lefrak EA, Pitha J, Rosenheim S, Gattlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
3. VonHoff DD, Layard MW,Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann InternMed. 1979;91:710-717. (Pubitemid 10218041)
4. Moncada S, Palmer RM, Higgs EA. Nitric oxide physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
5. Varin R, Mulder P, Richard V, et al. Exercise improves flow-mediated vasodilatation of skeletalmuscle arteries in rats with choronic heart failure: role of nitric oxide, prostanoids, and oxidant stress. Circulation. 1999;99:2951-2957. (Pubitemid 29258985)
6. Kilinc M, Balat A, Cekmen M, et al. Adrenomedullin and nitrite levels in children with dilated cardiomyopathy. Pediatr Cardiol. 2003;24:381-385. (Pubitemid 37021439)
7. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087-1094. (Pubitemid 26087012)
8. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. JMol Cell Cardiol. 1998;30:1215-1223. (Pubitemid 28327789)
9. Pacher P, Liaudet L, Bai P, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation. 2003;107:896-904. (Pubitemid 36241050)
10. Elbl L, Hrstkova H, Chaloupka V.The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr. 2003;162:690-696. (Pubitemid 37255501)
11. Bulock FA, Mott MG, Oakhill A, Martin RP. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child. 1996;75;416-422. (Pubitemid 26405682)
12. Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem. 1995;41:904-907.
13. Pihkala J, Happonen J, Virtanen K, et al.Cardiopulmonary evaluation of exercise tolerance after chest irradiation and anticancer chemotherapy in children and adolescents. Pediatrics. 1995;95:722-726.
14. Signal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in hearth: a concise review. JMol Cell Cardiol. 1987;19;817-828. (Pubitemid 17144746)
15. Mavinkurve-Groothuis AM, Kapusta L, Nir A, Groot-Loonen J. The role of biomarkers in the early detection of antracycline-induced cardiotoxiciy in children: a review of literature. Pediatr Hematol Oncol. 2008;25:655-664.
16. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardac troponin T in pediatric patients at risk formyocardial injury. Circulation. 1997;96:2641-2648. (Pubitemid 27451357)
17. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004;18:664-675. (Pubitemid 38451788)
18. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletalmyocytes of patients with choronic heart failure is associated with exercise intolerance. J AmColl Cardiol. 1999;33:959-965.
19. Habib FM, Springall DR, Davies GJ, et al. Tumor necrosis factor and inducible nitric oxide syntheses in dilated cardiomyopathy. Lancet. 1998;347:1151-1155.
20. Heymes C, Vanderheyden M, Bronzwaer JG, et al. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation. 1999;99:3009-3016. (Pubitemid 29270430)
21. Rakhit RD, Tousoulis D, Lefroy DC, Davies GJ. Differential nitric oxide synhase activity in ischemic and idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;84:737-738. (Pubitemid 29417970)
22. Winlaw DS, Smythe GA, Keogh AM, et al. Increased nitric oxide production in heart failure. Lancet. 1994;344:373-374. (Pubitemid 24248210)
23. Kalivendi SV,Kotamraju S, ZhaoH, et al.Doxorubicin induced apoptosis is associatedwith increased transcription of endothelial nitric oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem. 2001;276:47266-47276.
24. Weinstein DM, Mihm MJ, Bauer JA. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther. 2000;294:396-401. (Pubitemid 30434713)
25. Fadillioglu E, Yilmaz HR, Erdǒgan H, Sö̌güt S,Theactivities of tissue xanthine oxidase and adenosine deaminase and the levels of hydroxyproline and nitric oxide in rat heart subjected to doxorubicin: protective effect of erdosteine. Toxicology. 2003;191:153-158. (Pubitemid 37329460)
26. Sayed-Ahmed MM, Khattab MM, Gad MZ, Osman AM. Increased plasma endothelin and cardiac nitric oxide during doxorubicin-induced cardiomyopathy. Pharmacol Toxicol. 2001;89:140-144.
27. Barnabe N, Marusak RA, Hasinoff BB. Prevention of doxorubicin-induced damage to rat heart myocytes by arginine analog nitric oxide synthase inhibitors and their enantiomers. Nitric Oxide. 2003;9;211-216. (Pubitemid 38293003)
28. Elli M, Soylemezoglu O, Erbas D, et al. Plasma and urine nitric oxide levels in healthy Turkish children. Pediatr Nephrol. 2005;20:1605-1609. (Pubitemid 41554474)
29. Zhao G, Shen W, Zhang X, et al. Loss of nitric oxide production in coronary circulation after the development of dilated cardiomyopathy: a specific defect in the neural regulation of coronary blood flow. Clin Exp Pharmacol Physiol. 1996;23:715-721. (Pubitemid 26373919)
30. Guerra J, De Jesus A, Santiago-Borrero P, et al. Plasma nitric oxide levels used as an indicator of doxorubicin-induced cardiotoxicity in rats. Hematol J. 2005;5:584-588. (Pubitemid 40309624)
31. Kremer LC, van Dalen EC, OffringaM, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-termfollow-up study. J Clin Oncol. 2001;19:191-196. (Pubitemid 32063496)
32. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are assocaited with doxorubicin-induced cardiotoxicity. Circulation. 2005;112:3754-3762. (Pubitemid 43739516)
33. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum. 1996;55:7-20. (Pubitemid 26008891)
34. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915-918. Pediatric Hematology (Pubitemid 24292319)